Novo Nordisk shares dive 9% after heart medicine fails trial
· cnbc.com
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to ...